As of 2026-03-12, the Intrinsic Value of Rubius Therapeutics Inc (RUBY) is -14.47 USD. This RUBY valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.08 USD, the upside of Rubius Therapeutics Inc is -17,533.68%.
Based on its market price of 0.08 USD and our intrinsic valuation, Rubius Therapeutics Inc (RUBY) is overvalued by 17,533.68%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -14.47 - -14.47 | -14.47 | -17,533.68% |
| P/E | (67.31) - (79.99) | (71.92) | -86745.3% |
| DDM - Stable | (14.96) - (36.58) | (25.77) | -31146.6% |
| DDM - Multi | (11.56) - (23.21) | (15.56) | -18847.1% |
| Market Cap (mil) | 5.15 |
| Beta | 4.04 |
| Outstanding shares (mil) | 62.08 |
| Enterprise Value (mil) | -9.75 |
| Market risk premium | 4.60% |
| Cost of Equity | 14.33% |
| Cost of Debt | 5.00% |
| WACC | 9.00% |